Direct Biologics announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct Biologics is the first and only EV company to receive FDA Phase 3 approval for an Investigational New Drug…
eTurboNews Els articles són només per a subscriptors. La subscripció és GRATIS.
Els subscriptors inicien sessió aquí Feu clic aquí per subscriure-us GRATIS
Els subscriptors inicien sessió aquí Feu clic aquí per subscriure-us GRATIS
QUÈ TREURE D'AQUEST ARTICLE:
- Direct Biologics is the first and only EV company to receive FDA Phase 3 approval for an Investigational New Drug….
- Direct Biologics announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19.
- eTurboNews Els articles són només per a subscriptors.
